Supplementary Figure 1. Kaplan-Meier survival curve for enhancer of zeste homologue 2 (EZH2) according to the luminal B, human epidermal growth factor receptor 2 (HER2), and triple-negative breast cancer (TNBC) subtype. (A) Disease-free survival (DFS) ($p = 0.386$) and (B) overall survival (OS) ($p = 0.147$) in patients with HER2-negative luminal B type ($n = 72$). (C) DFS ($p = 0.634$) and (D) OS ($p = 0.782$) in patients with HER2-positive luminal B type ($n = 34$).
Supplementary Figure 1. Continued. (E) DFS ($p = 0.522$) and (F) OS ($p = 0.690$) in patients with HER2 type ($n = 44$). (G) DFS ($p = 0.367$) and (H) OS ($p = 0.535$) in patients with TNBC basal type ($n = 73$). (I) DFS ($p = 0.274$) and (J) OS ($p = 0.374$) in patients with TNBC non-basal type ($n = 30$).